Precision medicine

Precision medicine refers to a medical model that tailors diagnosis and treatment to the individual characteristics of each patient, including genetic makeup, environment, and lifestyle. Unlike traditional 'one-size-fits-all' approaches, it uses AI and machine learning to analyze large-scale biological datasets. According to NIST AI RTO principles and ISO 42001, these AI systems must be transparent, unbiased, and secure. In terms of data---centric risks, the EU's GDPR (Article 9) and Taiwan's Personal Data Protection Act (Article 27) strictly regulate the processing of genetic and biometric data, requiring robust de-identification and encryption protocols. For enterprise risk management (ERM), this means companies must treat AI-driven precision medicine tools as high-risk assets requiring continuous monitoring of both technical performance and regulatory compliance.

Implementation typically follows three steps: 1. Establish an AI governance framework based on ISO 42001 to define roles, responsibilities, and risk-adjusted decision-making protocols. 2. Implement data-centric security controls, including encryption, access control, and de-identification, to comply with GDPR and local privacy laws. 3. Deploy continuous monitoring systems to detect model drift, bias, and performance degradation. For example, a Taiwan-based diagnostic firm implemented a federated learning model to train AI on multi-hospital datasets without moving raw data, reducing data-related risks by 60% while improving diagnostic accuracy by 25%. Key performance indicators (KPIs) include model-specific error rates, compliance audit-pass rates, and data-related incident response times.

Taiwan enterprises face three primary challenges: 1. Regulatory complexity due to the divergence between local laws (Taiwan PIPA) and international standards (GDPR/HIPAA). Companies should adopt ISO 27701 as a baseline for global operations. 2. High-quality data acquisition costs, as genetic datasets are expensive to procure and clean. The solution is to partner with academic institutions or use synthetic data for initial model training. 3. AI ethics and bias risks, where models may perform differently across diverse ethnic groups. This requires rigorous validation against NIST AI RTO standards. The priority should be to first map the regulatory landscape, then pilot a small-scale AI application, and finally scale up once the risk-adjusted ROI is confirmed.

Winners Consulting Services Co., Ltd. specializes in Precision medicine for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact